Trial Profile
A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2016
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 06 Mar 2013 New trial record